WE TAKE YOU
A CHANGE IS COMING. ARE YOU READY?
WHO ARE WE
We are the first start-up to merge advanced electric, magnetic, & microfluidic 3D biofabrication technology with novel cyborganic technology to create high throughput tissues & organs with embedded bioelectronics, biosensors, and therapeutic agents.
We go beyond bioprinting to establish next generation applications in regenerative medicine, medical devices, & human-machine interfaces.
We believe that increasing the number of advanced hybrid technologies available for commercial use will set the new quality benchmark of biofabricated products and unlock new, more complex applications in tissue engineering and regenerative medicine. Novel applications include cyborganics, biomechatronics, biosensors, biorobotics, and human-machine interfaces.
By developing and supplying up-to-date, cutting-edge technologies in biofabrication and tissue engineering, we want to offer complete, standardized processes to our customers and make the field of biofabrication more accessible to any working professional with a vision. We empower researchers, developers and producers in various promising fields, thus facilitating their journey from the lab benchtop to the market.
Ourobionics team brings business and industry experts together with academic experts. We have 50+ years of combined experience in research and corporate environment.
JOHN ZANDBERGEN (CEO)
John Zandbergen is entrepreneur with 20+ years of international business experience. He has held sales and marketing leading positions with several companies before starting his own consultancy company providing business management and business development services to companies in life sciences, IVD and medical devices.
PROF. SUWAN N. JAYASINGHE (CSO)
Suwan leads the BioPhysics Group at University College London.150 publications in the field of tissue engineering and regenerative medicine including documented evidence of how his inventions of 3D bioelectrospraying, electrohydrodynamic jetting, and cell electrospinning overcome all of the limitations associated with extrusion bioprinting.
PROF. ALIREZA DOLATSHAHI-PIROUZ (CTO)
Alireza is a professor at DTU Nanotech, Denmark, with over 90 publications engineering, nanomaterials, regenerative medicine and cyborganic technology. He is developing printable, moldable and electrically conductive materials with self-healing capacities for applications within the emerging fields of flexible electronics, cyborganics, and soft robotics.
PROF. ALVARO MATA (CIO)
Alvaro is the Chair in Biomedical Engineering & Biomaterials, University of Nottingham specializing in in vitro biomimetic environments. He utilizes molecular printing within 3D environments to create dynamic and directed self-assembling systems, and molecularly-designed bioactive implants for applications in drug screening, regenerative medicine etc. He is the co-inventor of multiple biomaterial patents, including the first 4D self-assembly printable bioink.
ELPINIKI TSEKOU (CFO)
Elpiniki Tsekou is currently the global liquidity manager at Booking.com and completing a financial engineering masters at KU Leuven. She holds a master’s degree in business economics and finance and has an extensive background in financial planning and financial controller roles. For the past 10 years, she has worked in a range of controller and analyst and settlement agent functions in the investment and sustainability sectors. .
DORIS ZORIC (CMO)
Doris is currently pursuing a PhD degree in structural biology at the University of Gothenburg, Sweden, and assisting several early-stage startup ventures. Her scientific background is complemented with marketing and design skillset, with special focus on brand, content, website design and brochures.
STEPHEN G. GRAY (Advisor)
Stephen is a serial entrepreneur with over 10 years of building in management roles and advising companies in the sector of 3D Bioprinting and Regenerative Medicine. He also developed a skill set as a consultant for different startups using skills in data science, business intelligence, and non-dilutive funding assistance.
Ourobionics announces its co-founding team and a strategic alliance with Invitech to multiplex advanced tissue engineering technologies with 3D bioprinting and cyborganics
We are officially presenting our co-founding team, formed by professionals with over 50 years of combined expertise in tissue engineering, 3D biofabrication, regenerative medicine, and cyborganics/human-machine interfaces. We have also entered a partnership with Invictech that sets the grounds for developing a multiplex 3D biofabrication platform.
Ourobionics becomes a distribution partner for Humabiologics products in Europe
We are happy to announce Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market.